- Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT06271577.
- What is being tested: The clinical utility and diagnostic accuracy of smartphone-based ECG devices (AliveCor Kardia) for detecting and managing ST-elevation myocardial infarction (STEMI), compared to standard 12-lead ECG protocols in acute cardiac settings.
- Patient eligibility overview: Patients presenting with acute coronary syndrome symptoms or suspected STEMI in emergency care settings, with the ability to use smartphone-interfaced ECG technology; specific inclusion/exclusion criteria would be defined by the full trial protocol.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
AliveCor (www.alivecor.com) has developed several electrocardiogram (ECG) devices that interface with iOS and Android smartphones and tablets via various Kardia apps. The current Kardia family of devices can measure single lead and six limb-lead ECGs, depending on the device. KardiaMobile, KardiaMobile 6L, and KardiaMobile Card have FDA clearance for ECG rhythm recording. A modified single-lead Kardia smartphone 12-lead ECG was previously validated in the multicenter ST LEUIS study for the diagnosis of ST-Segment Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI). Recently, AliveCor developed a new device: AliveCor (AC)…
- : * Male or female > 18 years of age. * Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures. * Symptoms of chest pain upon presentation at the Emergency Department of the participating institution.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.